JCN Newswirehttp://www.japancorp.netJCN Newswire - Sector Press Release health.xmlen-usCopyright 2010 , JCN Newswirenewsroom@japancorp.netsaroj@japancorp.netJCN Newswirehttp://www.japancorp.net/images/jcnxml.jpghttp://www.japancorp.net8831JCN NewswireSundia MediTech Authorized ISO 9001:2008 Quality System Certificatehttp://japancorp.net/Article.Asp?Art_ID=22560saroj@japancorp.net (Saroj Shrestha)NEC's Facial Recognition Technology Achieves First Place in the Still-Face Dataset of the NIST Multiple Biometric Grand Challengehttp://japancorp.net/Article.Asp?Art_ID=22438saroj@japancorp.net (Saroj Shrestha)Fujitsu Launches SaaS Solution for Clinical Drug Trialshttp://japancorp.net/Article.Asp?Art_ID=22424saroj@japancorp.net (Saroj Shrestha)Eisai Submits Application for Additional Indication of Anti-arrhythmic Agent Tambocor(R) Tablets for Tachyarrhythmia in Paediatric Patients in Japanhttp://japancorp.net/Article.Asp?Art_ID=22416saroj@japancorp.net (Saroj Shrestha)Sysmex Announces Establishment of Overseas Subsidiary in Spain to Expand Life Science Businesshttp://japancorp.net/Article.Asp?Art_ID=22413saroj@japancorp.net (Saroj Shrestha)Submission of a New Drug Application for Pancreatic Enzyme Replacement Therapy Agent SA-001 in Japanhttp://japancorp.net/Article.Asp?Art_ID=22366saroj@japancorp.net (Saroj Shrestha)Xing Lin Medical Information Technology Announces Positioning in Healthcare Information System Market in Chinahttp://japancorp.net/Article.Asp?Art_ID=22329saroj@japancorp.net (Saroj Shrestha)MHI's First Radiotherapy Machine for Overseas to Begin Treatment at Brussels University Hospital (UZ Brussel)http://japancorp.net/Article.Asp?Art_ID=22311saroj@japancorp.net (Saroj Shrestha)Eisai Launches New Oral Jelly Formulation of Aricept(R), World's First Oral Jelly for Alzheimer's Disease Treatmenthttp://japancorp.net/Article.Asp?Art_ID=22305saroj@japancorp.net (Saroj Shrestha)Eisai and Quintiles Enter into a Strategic Collaboration to Develop Eisai's Anticancer Compoundshttp://japancorp.net/Article.Asp?Art_ID=22190saroj@japancorp.net (Saroj Shrestha)Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survivalhttp://japancorp.net/Article.Asp?Art_ID=22189saroj@japancorp.net (Saroj Shrestha)Eisai and TSD Japan Enter into a License and Joint Development Agreement of Denileukin Diftitox in Japanhttp://japancorp.net/Article.Asp?Art_ID=22169saroj@japancorp.net (Saroj Shrestha)MGH and NEC Start On-Site Evaluation of NEC Cancer Diagnosis Assistance System e-Pathologist at MGHhttp://japancorp.net/Article.Asp?Art_ID=22161saroj@japancorp.net (Saroj Shrestha)Eisai Opens Regional Office in Bahrainhttp://japancorp.net/Article.Asp?Art_ID=22150saroj@japancorp.net (Saroj Shrestha)Mitsibishi Corporation Announces Comprehensive Alliance with Sinopharm Group and Investment in Beijing Huahonghttp://japancorp.net/Article.Asp?Art_ID=22147saroj@japancorp.net (Saroj Shrestha)Abbott and Eisai Submit Application for Approval of Humira(R) for the Treatment of Crohn's Disease in Japanhttp://japancorp.net/Article.Asp?Art_ID=22068saroj@japancorp.net (Saroj Shrestha)Eisai and DNDi Enter Collaboration and License Agreement to Develop New Drug for Chagas Diseasehttp://japancorp.net/Article.Asp?Art_ID=22063saroj@japancorp.net (Saroj Shrestha)Eisai Submits Application for Additional Indication of its Proton Pump Inhibitor PARIET(R) for Non-erosive GERD in Japanhttp://japancorp.net/Article.Asp?Art_ID=22062saroj@japancorp.net (Saroj Shrestha)KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos(R) Tablets in China, India, Sri Lanka and ASEAN Countrieshttp://japancorp.net/Article.Asp?Art_ID=22061saroj@japancorp.net (Saroj Shrestha)Suprema Raises $36M in New Share Issuehttp://japancorp.net/Article.Asp?Art_ID=22006saroj@japancorp.net (Saroj Shrestha)